Healthcare Global Enterprises Results: Latest Quarterly Results & Analysis

Healthcare Facilities company Healthcare Global Enterprises announced H1FY25 & Q2FY25 results

Q2FY25 Financial Highlights:

• Revenue: Rs 5,535 million with change  14% YoY.
• EBITDA: Rs 1,042 million with change 21% YoY.
• PAT: Rs 180 million with change 33% YoY.

H1FY25 Financial Highlights:

• Revenue: Rs 10,791 million with change  14% YoY.
• EBITDA: Rs 1,970 million with change 21% YoY.
• PAT: Rs 301 million with change 42% YoY.

Operational Highlights:

• Overall ARPOB stood at Rs 45,188 vs. Rs 42,058 in Q2FY24, a growth of 7.4%.
• Overall AOR stood at 65.6% vs. 65.8% in Q2FY24.
• RoCE (Q2FY25 Annualized).
  • RoCE for Established centers stood at 15.8% vs. 15.7% in Q2FY24. RoCE pre-corporate allocations stands at 19.6%.
  • RoCE for Emerging centers stood at -10.7% vs. -13.2% in Q2FY24. RoCE pre-corporate allocations stands at -7.0%.
• Several regions delivered high double-digit revenue growth on YoY basis.
  • Markets like Kolkata and Ongole grew by 66% and 46% YoY respectively.
  • Nagpur, Nashik & Jaipur grew by 32%, 32% and 28% YoY respectively.
• HCC Hospital Ahmedabad, Phase III operationalized in Q2FY25.
• 5 units of HCG have been Accredited by NABH for the Digital Health Accreditation Standards namely KR, DR, Nashik, Borivali and Kolkata.
• Aligning with asset light strategy, PET Machines on Pay-per-use across other 3 centers namely Vijayawada, Chennai and HCC operationalized in Q2FY25.
• Advance replacement of Cyber-knife at KR completed and became operationalized in Q2FY25.
• Replacement of LINAC at DR completed and new machine is operationalized

B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises, said: "I am proud to announce strong financial and operational performance for quarter ended September 2024, a true reflection of the dedication and expertise of our exceptional team, from doctors to support staff, who work tirelessly to provide highquality care.

Having over decades of experience, we understand that cancer is a complex disease requiring a unique and focused approach to diagnosis and treatment. Our model centers on patient-centric, personalized care, ensuring that each patient receives treatment precisely tailored to their specific cancer type and stage of progression, and our outcomes are comparable to the best in the western world. With our network of hospitals spread across the country, we aim to provide this level of treatment to every patient battling cancer.

As we look to the future, HCG remains committed to pushing the boundaries of cancer treatment through the integration of advanced technologies and patient-centric innovations. With initiatives like Virtual OPD and centralized genomics, we aim to make high-quality cancer care more accessible and precise, empowering patients with cutting-edge diagnostics and treatment plans tailored to their unique needs. Our journey is made possible by the trust our stakeholders place in us, and we remain dedicated to advancing value-based cancer care across our growing network."

Raj Gore, CEO HealthCare Global Enterprises, said: “HCG has reported its best ever quarterly revenues of Rs 554 crores with a robust growth of 14% and EBITDA margins standing strong at 18.8% compared to 17.8% in same period last year. Proforma revenue growth including Vizag acquisition stands at 20% with EBITDA margins of 19%. This growth is on the back of increased volumes across modalities leading to operational leverage playing out well. We are confident of continuing this upward trend with our emerging centers ramping up and contributing to the growth.

Emerging centers grew by 32% and with our Kolkata center being a major growth driver, growing by 66% on a year on year basis, turning profitable in the current year with 9.2% EBITDA % in Q2, and we expect the momentum to continue in coming quarters.

Our digital initiatives have significantly boosted our patient funnel, raising digital channel revenue to 14% of overall revenue in Q2, up from 4% last year. We aim to achieve 25% of revenue through digital platforms over the next 3-5 years. In addition, our strategic acquisition of MG Hospital in Vizag is progressing well and in line with our expectations. This acquisition has been instrumental in enhancing our footprint in the region, allowing us to further expand our services and strengthen our presence in one of the key markets for cancer care.

Going forward, we aim to increase our presence across the country while scaling operations at our existing centers with a view to provide best cancer care to the people of the country. Additionally, we plan to establish more Centers of Excellence in the coming years, modeled after our premier facilities in Bangalore and Ahmedabad, equipped with state-of-the-art medical infrastructure and top clinical talent. As we move forward, we remain focused on our mission to deliver exceptional care, drive innovation, and positively impact the lives of those we serve.”

Result PDF

Healthcare Facilities company Healthcare Global Enterprises announced Q1FY25 results:

Financial Highlights: 

• Revenue: Rs 5,256 million, 14% YoY
• Adjusted EBITDA: Rs 929 million, 21% YoY
• PAT: Rs 121 million, 59% YoY

Operational Highlights:

• Overall ARPOB stood at Rs 44,342 vs. Rs 39,686 in Q1FY24, a growth of 12%
• Overall AOR stood at 65.7% vs. 66.9% in Q1FY24
• RoCE for Established centers stood at 14.1% vs. 15.5% in Q1FY24. RoCE pre-corporate allocations stands at 17.4%
• RoCE for Emerging centers stood at -9.3% vs. -15.2% in Q1FY24. RoCE pre-corporate allocations stands at -6.1%
• Kolkata grew by 73% for the quarter on a YoY basis
• Nagpur, South Mumbai, Nashik & Bhavnagar grew by 26%, 22%, 22% and 21% YoY respectively

Commenting on the results, B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises said, “As planned, we continue to deliver strong financials as well as operational excellence across the network. Our centers are performing as expected or even better.

During the quarter, we expanded our footprint and portfolio by virtue of the acquisition of Vizag-based Mahatma Gandhi Cancer Hospital and Research Institute. Going forward, Vizag will undoubtedly play a key role in shaping our growth strides. Having already established a strong brand in the region, we will in good time consolidate our presence to become the single largest player in the region.

Given our ethos of pursuing excellence as a continuum, our doctors, specialists, and clinicians remain unflinchingly focused on disruptive innovation by virtue of academics and research, which translates into novel therapies and breakthroughs enhancing the quality of life and outcomes for our patients. Thanks to our unique approach of providing our patients with the right treatment at the right time, our outcomes are comparable to those of leading cancer care institutions worldwide.

As we move forward, our commitment to providing innovation-focused, technologyenabled, value-based cancer care will help us expand our reach to serve more communities across new geographies.

I am immensely proud of Team HCG; it is the collective effort of every HCGian that has helped us serve the larger cause of our ultimate stakeholders, our patients, with conviction and credence and, in the process, has seen us carve a niche as a destination for cancer care in the country.”

Raj Gore, CEO HealthCare Global Enterprises added, “We are pleased to announce that our revenue for the quarter has increased by 16.7% year-over-year excluding revenues from discontinued MSR operations. Our EBITDA grew by 22.3% year-over-year, demonstrating significant operational leverage in our business. The EBITDA margin for Q1 was 17.3%, a 120 bps increase year-over-year, continuing the upward trend we have observed in recent quarters and remain optimistic about further improvements.

Our consistent revenue growth is driven by volume increases across modalities and enhanced operational performance, supported by the strong results of our established centers and the progress in our emerging centers. We have been diligently working to turn around operations at our emerging centers, and we are excited to report that our Kolkata center has shown promising growth and is now contributing to our overall EBITDA. We are confident that the emerging centers will see revenue growth and margin expansion over the next 12 months, significantly contributing to overall margins.

As we reflect on this quarter, we are inspired by the dedication and hard work of our entire team. Our focus on delivering exceptional cancer care and expanding our network continues to drive our success. With the momentum from our recent acquisition and the ongoing support of our partners, we are well-positioned for sustained growth and innovation. We look forward to building on this strong foundation as we continue our mission to improve patient outcomes and set new standards in cancer treatment.”

Result PDF

Healthcare Global Enterprises announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

• Revenue: Rs 4,946 million 12% YoY
• Adjusted EBITDA: Rs 941 million 21% YoY
• PAT: Rs 213 million  154% YoY

FY24 Financial Highlights:

• Revenue: Rs 19,121 million 13% YoY
• Adjusted EBITDA: Rs 3,374 million 11% YoY
• PAT: Rs 482 million 65% YoY

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, “We experience a deep sense of fulfilment to report a consistent benchmark-beating performance across all fronts for the quarter and the fiscal year ending FY24. Year after year, HCG has achieved sustainable cancer care outcomes comparable to premier centers in the world, thanks to our unique value-based care model and focused factory approach providing patients with the right treatment at the right time, using best in class talent, knowledge, technology, and infrastructure.

Given the mounting incidence of cancer in recent years, India has prudently enhanced its cancer diagnosis and treatment processes in the guiding light of visionary crusaders like HCG. We prioritize a deep engagement in academics and research alongside an unflinching focus on patient outcomes. In the past year, we have made significant triumphs, including the successful completion if comprehensive genomic profiling for over 1,000 cancer patients, executing complex surgeries, and launching our all-in-one mobile application, among other feats.

Our extensive presence in 18 regions across nine states, with one-third of our centers located in tier-II and tier-III cities, underscores our sterling commitment of providing affordable and quality cancer care for every cancer patient across India. Our ability and agility to build heartfelt relationships with patients is built on a rock-solid foundation of compassion and trust, which truly sets us apart in this crucial sector. As we get ready to lock horns with new challenges and keep pace with the evolving paradigms of tomorrow, we earnestly resolve to make a bigger difference in the lives of patients, our most valued stakeholders.”

Raj Gore, CEO HealthCare Global Enterprises Ltd. added, “We are delighted to report that our revenues grew by 12% for Q4FY24 on YoY basis. Our Adjusted EBIDTA (excl. ESOP cost) for Q4FY24 stood at Rs 94 crore, a growth of 21% YoY, with margins standing at 19.0%, an increase of 140 bps compared to the same period last year.

Over the year, we have taken multiple steps to enhance our operations and improve our profitability. After consistently achieving organic growth for 3-4 years, we're now poised to expedite HCG's expansion through strategic acquisitions. In addition to our expansion efforts in Indore, we are committed to further strengthening our presence in Bangalore. We are currently in the process of establishing two hospitals with 125 beds in North Bangalore and White field area, slated to be operational within the next 12 to 15 months. These state-of-the-art facilities will enhance our capacity to cater to the growing cancer care needs of the region.

Alongside, to enhance the patient experience and streamline access to healthcare services, we have introduced the 'HCG CARE' smart app suite. This innovative platform provides patients with seamless access to their medical records and treatment information with just one click. The app would also help us consistently engage with patients post treatments, to continue monitor adherence to treatment and follow up to improve outcome. Already, the app has benefited over 56,000 outpatients, with active participation from 300 consulting doctors on the digital platform.

Our patient-centric vision continues to guide us in making a meaningful difference in the lives of those we serve by redefining healthcare through global innovation. We pledge to uphold our commitment to “Adding Life to Years” in the coming financial years as well.”

Result PDF

Healthcare Global Enterprises announced Q3FY24 & 9MFY24 results:

Financial Performance

• Revenue: Q3FY24 revenue reached Rs 4,699 million, marking an increase of 11% YoY. Over 9MFY24, the revenue climbed to Rs 14,175 million, reflecting a growth of 13% YoY.
• Adjusted EBITDA: The company reported an adjusted EBITDA of Rs 826 million for Q3FY24, achieving a 7% rise YoY. For 9MFY24, adjusted EBITDA was Rs 2,455 million, indicating an 8% YoY increase.
• Profit After Tax: The Profit After Tax (PAT) for Q3FY24 was Rs 57 million, a decrease of 24% YoY. While for 9MFY24, the PAT stood at Rs 269 million.

Revenue Breakup

• Mature Centers: Q3FY24 revenue from mature centers was 790 million.
• Emerging Centers: Revenue from emerging centers in Q3FY24 reached 1,015 million.

EBITDA Breakup - Mature vs Emerging Centers

• Mature Centers: Demonstrated a YoY growth of 19.3%, with an increased revenue of Rs 3,323 million in Q3FY24 compared to Rs 3,065 million in Q3FY23.
• Emerging Centers: Shown a YoY growth of 65.7%, with a revenue hike from Rs 122 million in Q3FY23 to Rs 126 million in Q3FY24.

Operational KPIs (Oncology)

• OPD Footfall: Q3FY24 experienced 110,000 footfalls, as compared to 91,000 in Q3FY23.
• Chemo Sessions Administered: The company administered 36,000 chemo sessions in Q3FY24 whereas it was 34,000 in Q3FY23.
• LINAC Capacity Utilizations: Utilization increased to 61% in Q3FY24 from 60% in Q3FY23.
• In-Patient Bed Occupancy: Saw a slight decrease to 52% in Q3FY24 from 57% in the previous year.

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises said, “India is at the cusp of significant demographic change leading to a doubling of population aged over 60 years by 2050. Cancer incidence is expected to increase by 77% during this period. HCG, with its network of 22 Cancer Centers and expansion plans is poised to play a dominant role in serving the diagnostic and treatment needs of the forecasted demand.

HCG's performance for the quarter serves as evidence of its progress in advancing towards focused cancer care, where research and collaboration are the key drivers for improving patient outcomes. By leveraging these unique value propositions, we are able to provide targeted treatments such as adaptive radiotherapy and immunotherapy to our patients. Moreover, our integration of technology into patient care processes, including computational work and Al platforms, allows us to continuously be on the leading edge of the change, creating a differential in the way cancer has evolved.

At HCG, we have always embraced technology and innovation to be at the forefront of advancement in cancer care. We have consistently adopted cutting-edge solutions to ensure that we provide the highest quality healthcare to our patients. Our ability to deeply connect with patients is built on a foundation of compassion and trust that is unmatched, which is what truly sets HCG apart from others in our field. We remain committed to continue making a meaningful difference in the lives of those we serve in making Cancer a chronic disease."

Result PDF

Healthcare Global Enterprises announced Q1FY24 results:

• Revenue of Rs 4,607 million in Q1FY24, up 13% YoY.
• EBITDA of Rs 764 million in Q1FY24, up 5% YoY.
• Profit After Tax of Rs 110 million in Q1FY24, up 17% YoY.
• Overall ARPOB stood at Rs 39,686 vs. Rs 38,286 in Q1FY23.
• Overall AOR stood at 66.9% vs. 61.0% in Q1FY23, a rise of 590 bps.

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises said, “HCG’s oncology network, through its presence and depth, uniquely positions the company to address the growing cancer burden in India holistically, while delivering quality cancer care and outcomes.

HCG's role today goes beyond mere service provision, extending into pioneering research and academia. We consistently encourage our medical professionals to delve into research, clinical trials, and active participation in global medical conferences and academic pursuits. We are currently working on the low dose immunotherapy & also collaborating with various MNC’s for developing technologies and AI based framework for treatments.

HCG strives to be the trusted healthcare partner for every individual battling cancer. We are honored to have earned the trust of our patients and the communities we serve and remain committed to upholding that trust every day."

Result PDF

Healthcare Global Enterprises announced Q3FY23 results:

• Q3FY23 & 9MFY23:
  • Revenue Rs 4,247 million is up by 19% for Q3FY23 YoY.
  • Adjusted EBITDA  Rs 812 million is up by 28% for Q3FY23 YoY.
  • Profit after Tax Rs 75 million turns positive for Q3FY23 YoY.
  • Revenue Rs 12,527 million is up by 21% for 9MFY23 YoY.
  • Adjusted EBITDA Rs 2,378 million is up by 35% for 9MFY23 YoY.
  • Profit after Tax Rs 209 million turns positive for 9MFY23 YoY.

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, of HealthCare Global Enterprises Ltd. said, “At HCG, we strive to provide the best-in-class treatments for our patients across the value chain. We have been focusing on consistently upgrading our skill set with deep domain knowledge, upgradation of technology & urge to treat cancer for the best possible outcomes for every single patient under the HCG horizon.

Technology and innovation play a pivotal role in enhancing healthcare systems, increasing access to healthcare services, and reducing the costs of therapies and consultations. It is the intelligent deployment of technology that serves the larger cause of healthcare. At HCG, patient care is approached holistically based on risk and severity of disease - from pre-admission to post-discharge – and is aimed at enhancing outcomes, lowering costs, and bettering resource management. Whether Linac technology, Teleradiology, Bioinformatics, Genomics, Robotic surgery, Digital pathology, or Adaptive AI, HCG's technology adoption is unflinchingly focused on patient outcomes.

Our focus has been on Oncology in conjunction with local partners, has helped us built a strong legacy as a World-class Oncology Treatment Center &Institution across India.”

Mr. Raj Gore, CEO of HealthCare Global Enterprises Ltd. added, “I am extremely happy to share that we have once again outgrown the industry growth, and our revenues for Q3FY23 grew by 19% on a YoY basis to Rs 4,247 million. With accelerated awareness in the society for Cancer care &diagnosis and HCG, being a trusted brand in the medical fraternity for Cancercare, we expect the revenue growth to improve and margins to enhance due to operating leverage play. 

We have seen growth in our volumes & patient count across modalities and with increased awareness, investments in digital technology, marketing initiatives & positive outcomes, we are optimistic of sustaining the growth momentum.

At HCG, we believe in patient-centric care, focusing on accessible oncological services, advanced treatments, and high-quality care & outcomes. Over the years we have emerged as a responsible brand earning the trust of thousands of patients and the admiration of the community which has led us to be the leader in most of the markets, we are present in. Going forward, we continue to invest in HCG brand and penetrate deeper into the markets of our core geography and attain leadership position in newer territories through superior treatment & outcomes.”

Result PDF

Healthcare Global Enterprises announced Q2FY23 results:

• Q2FY23:
  • Revenue is Rs 4,200 million; up 19% YoY for Q2FY23 
  • Adjusted EBITDA is Rs 810 million; up 28% YoY for Q2FY23 
  • PAT is Rs 74 million; turns positive for Q2FY23 YoY
• H1FY23
  • Revenue Rs 8,281 million; up 23% YoY for H1FY23 
  • Adjusted EBITDA is Rs 1,566 million, up 40% YoY for H1FY23 
  • PAT is Rs 134 million; turns positive for H1FY23 YoY

BS Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd, said, "HCG chain of dedicated cancer centres is consistently moving up the value chain of high-quality clinical care powered by high-end technology. Our Bangalore COE, which is one of India’s largest dedicated cancer care hospitals has recently launched India’s first Varian Ethos™ therapy, an Artificial Intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy. It uses augmented intelligence, a convergence of people and artificial intelligence (AI) working together for better outcomes & higher success rates while maintaining the quality of life. This game-changing radiation therapy personalizes cancer care using adaptive intelligence based on the patient’s anatomy and the position of the tumour at the time of treatment.

At HCG, we are equally focused and engaged in academics and research, we are very proud to announce that we have over 170 fellowship programs and different DNB programs in oncology, not only in Bangalore, but also in Tier 2, and Tier 3 cities. In research, for October, we have had nine new publications, and a significant number of them have been podium presentations, till date we have published more than 750 research papers.

Our focus has been on Oncology in conjunction with local partners, which has helped us build a strong legacy as a World-class Oncology Treatment Center & Institution across India."

Raj Gore, CEO HealthCare Global Enterprises Ltd, added, "We are happy to report another strong financial performance for the quarter that ended September 2022. Our consolidated revenue for Q2FY23 stood at Rs 4,200 mn, a growth of 19% on a YoY basis. Our focused efforts on cost rationalization coupled with strong revenue growth have resulted in a marginal expansion of 230 bps, leading to an adjusted EBITDA margin of 18.9% in H1FY23. Adjusted EBIDTA for H1FY23 stood at Rs 1,566 mn as compared to Rs 1,121 mn in H1FY22, a growth of 40% on YoY basis. As a result of consistent revenue growth & margin expansions, our reported PAT (excl. Exceptional items) has increased to Rs 74 Mn for Q2FY23 as compared to Rs 8.3 Mn in Q2FY22.

While our mature centres continue to show higher than the market growth rate, the growth strategies implemented for the emerging centres have started showing promising results. Jaipur centre has more than doubled its revenue whereas Kolkata and Mumbai have grown by 40% & 30% respectively on a Y-o-Y basis in the current quarter

Our differentiated and specialised cancer care along with strong brand positioning have enabled us to attain leadership position in 13 out of 18 locations where we are present. Going forward, we will continue to invest in HCG brand to make it the preferred choice for cancer patients across India. We are optimistic of improving our market share & strengthening our leadership position."

Result PDF

Healthcare Global Enterprises announced Q1FY23 Result :

• Overall ARPOB stood at Rs. 38,454 vs. Rs. 36,316 in Q1 FY22, a growth of 5.9%
• Overall AOR stood at 64.6% vs. 57.8% in Q1 FY22, a rise of 680 basis points
• EXISTING CENTERS:
  • ARPOB stood at Rs. 40,606 vs. Rs. 35,979 in Q1 FY22, a growth of 12.9%
  • AOR stood at 64.0% vs. 59.4% in Q1 FY22, a rise of 460 basis points
  • RoCE stood at 19.0% vs. 15.4% in FY22, a rise of 360 basis points
• NEW CENTERS:
  • ARPOB stood at Rs. 32,968 vs. Rs. 32,295 in Q1 FY22, a growth of 2.1%
  • AOR stood at 66.1% vs. 53.5% in Q1 FY22, a rise of 1,260 basis points
  • RoCE stood at -4.6% vs. -8.3% in FY22

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, HCG is a leading Oncology care provider, which is patient centric, technology-oriented and outcome based. Our focus has been on Oncology in conjunction with local partners in some areas, which has built a strong legacy as a World-class Oncology Institution and a go-to brand for oncological treatment & services across India. Our focus on strong clinical talent, good infrastructure, technology, and timely upgradation of the same has enhanced or ability to deliver exceptional clinical outcomes equal to or better than global standards. And in the very near future, we are putting together the data on Head & Neck and Breast Cancer on these outcomes. HCG today is not only a service provider but has taken a lead role in Research and Academics. Recently, we have acquired Next Generation Sequencer and in the process of acquiring circulating tumour cells (CTC platform). These additions are already enhancing our capabilities in precision diagnosis leading to early detection of recurrent tumours and genomic guided therapy. We have a separate tumour board for this with relevant expertise. In addition, we have introduced Enterprise RIS PACS, in collaboration with Siemens for the first time in the country for AI based precision imaging which will enhance our research capabilities. Further, HCG is introducing first of its kind in the country, AI enabled Adoptive Radiotherapy in our Centre of Excellence which will provide precision radiation oncology.

Mr. Raj Gore, CEO HealthCare Global Enterprises Ltd. added, We are happy to report robust growth for quarter ended June 2022. Our consolidated revenues for Q1FY23 grew by 26% on YoY basis and we have reported PBT of Rs. 10 crs for Q1FY23 as compared to loss of Rs. 9 crs in Q1FY22. We are also happy to report that we have been able to successfully accelerate the financial performance for HCG over the last 8 quarters. Our revenues have increased by ~1.7x since Q2FY21 on a quarterly run rate basis. Correspondingly our EBIDTA in absolute terms have grown by 2.4x times over the last eight quarters and have been able to achieve consecutive PBT positive quarter. We have been working on multiple fronts to take HCG to greater heights by constantly improving holistic value that we offer to our patients and thus create value for the business in a sustainable manner. Four key areas of our strategic roadmap that we are currently working on are: 1) Digital transformation, 2) Cost optimization and efficiency enhancement, 3) Growth of Medical Value Travel, 4) Inorganic acquisitions. We are confident of maintaining our growth momentum going forward.

Result PDF

Healthcare Global Enterprises announced Q4FY22 results:

• Q4FY22:
  • Consolidated Income from Operations (“Revenue”) was Rs 3,646 Mn as compared to Rs 2,981 million in the corresponding quarter of the previous year, reflecting a YoY growth of 22.3%
  • Consolidated Profit Before Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was Rs 661 million, as compared to Rs 438 million in the corresponding quarter of the previous year, a growth of 51.2% YoY
  • Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“Operating EBITDA”), was Rs 631 million, as compared to Rs 394 million in the corresponding quarter of the previous year, a growth of 60.4% YoY
  • Operating EBITDA for Existing centers was Rs 610 million, a growth of 38.6% YoY, reflecting an Operating EBITDA margin of 22.0%
  • Operating EBITDA from New centers was Rs 21 million, as compared to loss of Rs (46) million in the corresponding quarter of the previous year
  • Proforma PAT was Rs 67 Mn, as compared to a loss of Rs (155) million in the corresponding quarter of last year, after adjusting below and tax implications there of;
    • Onetime project fee of Q4’22 Rs 25 million
    • ESOP Scheme expense of Q4’22 Rs 19 million
• FY22:
  • Consolidated Income from Operations (“Revenue”) was Rs 13,978 million as compared to Rs 10,134 million in the previous year, reflecting a YoY growth of 37.9%
  • Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”), was Rs 2,380 million, as compared to Rs 1,266 million in the corresponding quarter of the previous year, a growth of 88.0% YoY
  • Operating EBITDA for Existing centers was Rs 2,308 million, reflecting an Operating EBITDA margin of 21.5%
  • Operating EBITDA from New centers was Rs 72 million, as compared to loss of Rs (157) million in the previous year
  • Proforma PAT was Rs (13) Mn, as compared to a loss of Rs (980) million in the previous year, after adjusting below and tax implications there of;
    • Impairment of NCR project Rs 472 million
    • Exceptional gain of Rs (1419) million arising out of Strand and Suchirayu acquisition
    • Onetime project fee of FY’22 Rs 45 million
    • ESOP Scheme expense of FY’22 Rs 55 million
    • DTA recognized on tax expense through the year, on account of discontinuation of Kochi project, Rs (25) million

Commenting on the results, Dr. B.S. Ajaikumar, Executive Chairman, HealthCare Global Enterprises Ltd. said, “HCG has carved a niche as the cancer care destination of choice across all key areas of clinical, research, and academic excellence. Our phenomenal growth over the years bears testimony to the fact that cancer can be considered just like any other chronic disease, however curable. This year, we have added over 40 oncologists to our growing team which takes our doctor’s strength to over 450 which is the largest in the country in Oncology. We continue to employ the latest and most advanced techniques of cancer diagnosis and treatment enabling us to serve a greater number of patients with an objective of quality outcome. In a landmark development, we introduced Microsoft HoloLens, the next-gen holographic headset, heralding a new era of virtual reality at our enterprise. Through a pioneering industry initiative, we have brought healthcare training and medical education to the Metaverse by publishing 200 hours of virtual reality content across multiple subspecialties.

Patients are our most important stakeholders. To serve them more effectively, we have invested in a robust digital platform employing cutting-edge technologies for end-to-end patient engagement. The crux of our high quality of care across the length and breadth of the country is to ensure the right treatment, the very first time.

Going forward, we believe our robust cancer care ecosystem will continue to deliver impressive returns. Cancer therapies are undergoing a defining change every 75 days. Thanks to our enhancement of knowledge and innovations, we are able to relentlessly manage the cancer care in a progressive way. Backed by our research labs and the clinical trials, we are uniquely positioned to enhance our diagnostic capabilities and offerings, as also redefine precision medicine with end-to-end expertise spanning bioinformatics, genomics and research. This will enable us to deliver tangible patient outcomes with greater precision over the long term.

Academics and Research go hand in hand with patient care and our capabilities in this regard makes us the benchmark in cancer care treatment. We are happy to share that our Centre of Excellence in Bangalore has been ranked #1 in the country.”

Result PDF